ArticleBMC medical ethics2016
Buying and selling human eggs: infertility providers' ethical and other concerns regarding egg donor agencies.
Article in BMC medical ethics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Reproductive Donors' Needs and Preferences: A Mixed-methods Systematic Review.International journal of community based nursing and midwifery · 2025Pooled it
- Stakeholders' experiences and perspectives of reproductive genetic carrier screening in gamete donation: a scoping review.Human reproduction (Oxford, England) · 2025Article
- Egg donation advertisements: addressing the regulatory gap.Journal of assisted reproduction and genetics · 2025Article
- Alignment between expectations and experiences of egg donors: what does it mean to be informed?Reproductive biomedicine & society online · 2021Article
- Oocyte Biobanks: Old Assumptions and New Challenges.Biotech (Basel (Switzerland)) · 2021Article
- Women's viewpoints on egg freezing in Austria: an online Q-methodology study.BMC medical ethics · 2021Article
- Challenges, Dilemmas and Factors Involved in PGD Decision-Making: Providers' and Patients' Views, Experiences and Decisions.Journal of genetic counseling · 2018Article
- Impediments to communication and relationships between infertility care providers and patients.BMC women's health · 2018Article
- Gatekeepers for infertility treatment? Views of ART providers concerning referrals by non-ART providers.Reproductive biomedicine & society online · 2018Article
- How Infertility Patients and Providers View and Confront Religious and Spiritual Issues.Journal of religion and health · 2018Article
- Unconventional combinations of prospective parents: ethical challenges faced by IVF providers.BMC medical ethics · 2017Article
- How much is a child worth? Providers' and patients' views and responses concerning ethical and policy challenges in paying for ART.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
backgroundEgg donor agencies are increasingly being used as part of IVF in the US, but are essentially unregulated, posing critical ethical and policy questions concerning how providers view and use them, and what the implications might be.
methodsThirty-seven in-depth interviews of approximately 1 h were conducted - with 27 IVF providers and 10 patients.
resultsClinicians vary in their views and interactions concerning egg donor agencies, ranging widely in whether and how often they use agencies. Agencies may offer egg recipients increased choices, but raise ethical and other concerns regarding respect for donors as individuals (e.g., adequacy of informed consent), potential harms, justice (e.g., concerns about possible eugenics - by encouraging and facilitating selection and marketing of facts for offspring), and donors constituting a vulnerable group. The quality of agencies appears to vary considerably, from acceptable to problematic. Agencies' medical and psychological screenings of donors can range, and be minimal. Not all agencies adequately track donors' prior numbers of donations, or share the relevant records with clinics. Clinics may find that potential donors have genetic mutations and medical problems about which they were unaware. Yet agencies and clinics do not provide care for such donors, generating stress. Dissemination of donors' personal data can potentially threaten confidentiality. Questions emerge of whether increased monitoring/oversight of agencies may be beneficial.
conclusionsThese data, the first to examine providers' views and interactions regarding egg donor agencies, suggest wide variations in quality and use of agencies, and have critical implications for practice, policy, education and research. Given the potential limitations of the current model of self-regulation of agencies, the present data suggest needs to consider stronger professional guidelines or possible governmental regulations to establish, require and enforce higher standards for agencies to follow, regarding advertising to potential donors and recipients, arranging for appropriate informed consent concerning risks and benefits involved, and for quality control. Appropriate informed consent should be obtained from potential egg donors, including the fact that they may learn about mutations or medical problems about which they were unaware, but for which they will not receive treatment as part of this process. Enhancing understanding among the public-at-large about what egg donation entails may also be helpful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.